<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4512">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243112</url>
  </required_header>
  <id_info>
    <org_study_id>090520</org_study_id>
    <nct_id>NCT01243112</nct_id>
  </id_info>
  <brief_title>Effectiveness Study of Different Local Anesthetic Mixtures</brief_title>
  <acronym>CA</acronym>
  <official_title>Onset and Duration of Effect of Lidocaine, Bupivacaine, and Lidocaine/Bupivacaine Mixture With Epinephrine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scott and White Hospital &amp; Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scott and White Hospital &amp; Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose and Background The purpose of this research study is to investigate the benefits of
      mixing lidocaine and bupivacaine for numbing the skin. Lidocaine and bupivacaine are two
      commonly used medications to numb the skin for minor procedures. Lidocaine has a faster
      onset. Bupivacaine has a longer duration. They are often combined with epinephrine to
      increase the length of action. These medications are used to control pain at the time of the
      operation and to decrease discomfort immediately afterward. Participating in the study
      involves injection of local anesthetic containing lidocaine, bupivacaine, and lidocaine and
      bupivacain with epinephrine at 4 sites on the forearm. Your participation will potentially
      improve the administration of these medications in persons undergoing a variety of
      procedures. You will be one of approximately 25 healthy volunteer subjects in this research
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Procedures

      During your participation the following procedures will be completed:

        -  You will be asked to read over and sign this consent form, if you choose to participate

        -  You will be asked demographic information and your medical history will be obtained

        -  If you are eligible to participate, the palm side of your forearm will be marked for
           the location of the treatments

        -  Four small injections will be made into the palm side of your forearms with the local
           anesthetic mixtures (you will not know which injection is used at each of the four
           injection sites)

        -  A small needle will be used for pinprick sensation to determine when numbness begins
           and ends

      Length of Study and Number of Visits This study begins at the time the medications are
      injected and is completed when sensation has completely returned. The study will last
      between 6 and 12 hours. During this time, you may perform low intensity tasks including
      reading, typing, and writing. You must remain in the study location as the sites will
      frequently be examined.

      Exclusions

      You should not participate in this study if any of the following apply to you:

        -  You are pregnant

        -  You have an allergy to lidocaine or bupivacaine

        -  You have a history of heart disease (including a prior heart attack, heart dysfunction,
           or heart failure)

      There may be other criteria that you have to meet to be eligible for this study. The study
      team can discuss these with you to determine whether you qualify.

      Discomfort and Risks Risks associated with the injections include temporary discomfort at
      the injection site and possible infection. It is also possible that you have an allergic
      reaction or side effect to the medications that are being used.

      Benefits There is no direct benefit to you for participating in this study. Your
      participation will potentially improve the administration of these medications in persons
      undergoing a variety of procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Length of Action</measure>
    <time_frame>Up to 12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time from onset of local anesthesia until cessation of effect by sensation of sharp measured in 15 minute increments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of Action</measure>
    <time_frame>Up to 5 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from infusion of local anesthetic to loss of sensation to sharp.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Lidocaine w/ Epi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2ml 1% Lidocaine with Epinephrine (1:100,000)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine with epi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2 ml 0.25% Bupivacaine with epinephrine (1:200,000)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose Lido and Bupi w/ Epi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2ml 0.5% Lidocaine + 0.125% Bupivacaine with Epinephrine (1:150,000)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Lido and Bupi with epi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2ml 1% Lidocaine + 0.25% Bupivacaine with Epinephrine (1:150,000)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Lidocaine with Epinephrine (1:100,000)</intervention_name>
    <description>0.2ml Intradermal injection once.</description>
    <arm_group_label>Lidocaine w/ Epi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.25% Bupivacaine with Epinephrine (1:200,000)</intervention_name>
    <description>0.2ml Intradermal injection once.</description>
    <arm_group_label>Bupivacaine with epi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)</intervention_name>
    <description>0.2ml Intradermal injection once.</description>
    <arm_group_label>Low dose Lido and Bupi w/ Epi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)</intervention_name>
    <description>0.2ml Intradermal injection once.</description>
    <arm_group_label>High Dose Lido and Bupi with epi</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-60

        Exclusion Criteria:

          -  Pregnancy

          -  allergy to local anesthetics

          -  history of heart disease or diabetes
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James B Collins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scott and White Healthcare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raman C Mahabir, MD</last_name>
    <role>Study Director</role>
    <affiliation>Scott and White Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scott &amp; White</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <lastchanged_date>October 25, 2011</lastchanged_date>
  <firstreceived_date>November 17, 2010</firstreceived_date>
  <firstreceived_results_date>September 15, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scott and White Hospital &amp; Clinic</investigator_affiliation>
    <investigator_full_name>James Collins</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited by hospital mailing list with 25 subjects enrolled over May 2010 until September 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Group</title>
          <description>0.2 ml 1% Lidocaine with Epinephrine (1:100,000), 0.2 ml 0.25% Bupivacaine with Epinephrine (1:200,000) 0.2 ml 0.5% Lidocaine and 0.125% Bupivacaine with Epinephrine Epinephrine (1:150,000) 2 ml of 1% Lidocaine and 0.25% Bupivacaine with Epinephrine (1:150,000)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Group</title>
          <description>0.2 ml 1% Lidocaine with Epinephrine (1:100,000), 0.2 ml 0.25% Bupivacaine with Epinephrine (1:200,000) 0.2 ml 0.5% Lidocaine and 0.125% Bupivacaine with Epinephrine Epinephrine (1:150,000) 2 ml of 1% Lidocaine and 0.25% Bupivacaine with Epinephrine (1:150,000)</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="36" spread="9.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Action</title>
        <description>The time from onset of local anesthesia until cessation of effect by sensation of sharp measured in 15 minute increments.</description>
        <time_frame>Up to 12 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>A calculation was made to power the study appropriately to determine a difference of 5 minutes based on previous studies which did not include the use of epinephrine.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>0.2 ml 1% Lidocaine with Epinephrine (1:100,000), 0.2 ml 0.25% Bupivacaine with Epinephrine (1:200,000) 0.2 ml 0.5% Lidocaine and 0.125% Bupivacaine with Epinephrine Epinephrine (1:150,000) 2 ml of 1% Lidocaine and 0.25% Bupivacaine with Epinephrine (1:150,000)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Length of Action</title>
            <description>The time from onset of local anesthesia until cessation of effect by sensation of sharp measured in 15 minute increments.</description>
            <units>minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>1% Lidocaine With Epinephrine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.63" spread="1.85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>0.25% Bupivacaine With Epinephrine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.02" spread="1.46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>0.5% Lidocaine and 0.125% Bupivacaine With Epineph</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.48" spread="1.76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1% Lidocaine and 0.25% Bupivacaine With Epinephrin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.16" spread="1.60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis is that no difference would be measured between treatment arms.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.359</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Onset of Action</title>
        <description>Time from infusion of local anesthetic to loss of sensation to sharp.</description>
        <time_frame>Up to 5 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>0.2 ml 1% Lidocaine with Epinephrine (1:100,000), 0.2 ml 0.25% Bupivacaine with Epinephrine (1:200,000) 0.2 ml 0.5% Lidocaine and 0.125% Bupivacaine with Epinephrine Epinephrine (1:150,000) 2 ml of 1% Lidocaine and 0.25% Bupivacaine with Epinephrine (1:150,000)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Onset of Action</title>
            <description>Time from infusion of local anesthetic to loss of sensation to sharp.</description>
            <units>second</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>1% Lidocaine With Epinephrine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29" spread="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>0.25% Bupivacaine With Epinephrine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19" spread="41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>0.5% Lidocaine and 0.125% Bupivacaine With Epineph</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26" spread="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1% Lidocaine and 0.25% Bupivacaine With Epinephrin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12" spread="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.490</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7/24/10 to 8/28/10</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Group</title>
          <description>0.2 ml 1% Lidocaine with Epinephrine (1:100,000), 0.2 ml 0.25% Bupivacaine with Epinephrine (1:200,000) 0.2 ml 0.5% Lidocaine and 0.125% Bupivacaine with Epinephrine Epinephrine (1:150,000) 2 ml of 1% Lidocaine and 0.25% Bupivacaine with Epinephrine (1:150,000)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Collins, MD</name_or_title>
      <organization>Scott &amp; White Healthcare</organization>
      <phone>254-724-7508 ext 0612</phone>
      <email>jbcollins@swmail.sw.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
